Sarepta Therapeutics to cut 500 jobs amid restructuring
Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected …
Post
-
-
Thermo Fisher acquires Sanofi’s steriles manufacturing site in US
Thermo Fisher Scientific has signed an agreement for the acquisition of Sanofi’s steriles manufacturing site located in Ridgefield in the …
-
PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
-
UK government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
-
GSK’s Blenrep US comeback hindered by eye safety concerns
GSK’s plan to bring blood cancer drug Blenrep (belantamab mafodotin) back to markets has hit a stumbling block, after the …
-
GSK’s Blenrep US comeback hindered by eye safety concerns
GSK’s plan to bring blood cancer drug Blenrep (belantamab mafodotin) back to markets has hit a stumbling block, after the …
-
Why global 3PL providers are essential to easing supply chain challenges
With tighter budgets, regulatory challenges, and uncertainty from tariffs, pharmaceutical companies are turning to third-party logistics (3PL) suppliers to deliver …
-
Navamedic completes dne pharma acquisition
Oslo, Norway-headquartered Navamedic has completed its previously announced acquisition of dne pharma's business for Nkr225m ($22m). This acquisition comprises dne pharma's …
-
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery …
-
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing …
-
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in …
-
Vertex and NHS England agree reimbursement for Alyftrek
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows a …
-
LEO Pharma secures rights to Boehringer’s Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening …
-
Health Canada extends Evkeeza approval for children with HoFH
Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) as an adjunct to diet and …
-
WHO endorses Gilead’s Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences’ newly approved injectable version of lenacapavir to fight …
